- Home
- TTNP vs PPBT Comparison
TTNP vs PPBT Comparison
Compare TTNP & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TTNP
- PPBT
- Stock Information
- Founded
- TTNP 1991
- PPBT 2010
- Country
- TTNP United States
- PPBT Israel
- Employees
- TTNP N/A
- PPBT N/A
- Industry
- TTNP Biotechnology: Biological Products (No Diagnostic Substances)
- PPBT Biotechnology: Pharmaceutical Preparations
- Sector
- TTNP Health Care
- PPBT Health Care
- Exchange
- TTNP Nasdaq
- PPBT Nasdaq
- Market Cap
- TTNP 5.4M
- PPBT 6.2M
- IPO Year
- TTNP 1996
- PPBT N/A
- Fundamental
- Price
- TTNP $4.93
- PPBT $2.31
- Analyst Decision
- TTNP
- PPBT Strong Buy
- Analyst Count
- TTNP 0
- PPBT 1
- Target Price
- TTNP N/A
- PPBT $33.00
- AVG Volume (30 Days)
- TTNP 49.3K
- PPBT 269.4K
- Earning Date
- TTNP 08-26-2025
- PPBT 08-06-2025
- Dividend Yield
- TTNP N/A
- PPBT N/A
- EPS Growth
- TTNP N/A
- PPBT N/A
- EPS
- TTNP N/A
- PPBT N/A
- Revenue
- TTNP N/A
- PPBT N/A
- Revenue This Year
- TTNP N/A
- PPBT N/A
- Revenue Next Year
- TTNP N/A
- PPBT N/A
- P/E Ratio
- TTNP N/A
- PPBT N/A
- Revenue Growth
- TTNP N/A
- PPBT N/A
- 52 Week Low
- TTNP $3.03
- PPBT $2.00
- 52 Week High
- TTNP $14.80
- PPBT $13.95
- Technical
- Relative Strength Index (RSI)
- TTNP 62.92
- PPBT 49.88
- Support Level
- TTNP $4.64
- PPBT $2.11
- Resistance Level
- TTNP $5.17
- PPBT $2.31
- Average True Range (ATR)
- TTNP 0.29
- PPBT 0.16
- MACD
- TTNP 0.11
- PPBT 0.01
- Stochastic Oscillator
- TTNP 83.67
- PPBT 72.73
About TTNP Titan Pharmaceuticals Inc.
Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.